Morgan Stanley Viridian Therapeutics, Inc.\De Call Options Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VRDN
# of Institutions
178Shares Held
76.6MCall Options Held
581KPut Options Held
439K-
Black Rock Inc. New York, NY4.77MShares$91.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$84.7 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$74.4 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$71.9 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$66.1 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $765M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...